Laurus Labs Q1 FY27: dates, rally, FY26 metrics

Stock action ahead of the Q1 FY27 update

Laurus Labs’ share price performance in the April to June 2026 quarter (Q1 FY27) has drawn attention after the stock posted its sharpest quarterly rally in five years, according to the data provided. The share price rose 53% during Q1 FY27. The stock also hit a record high of ₹1,530.30 on the BSE.

A trading snapshot included in the material showed the stock at ₹1,518 at 02:28 PM on Tuesday, about 1% higher, while the BSE Sensex was indicated at 76,730 with a flat trend. Separately, another snapshot in the same set of inputs listed the current price at ₹1,454 with a -1.81% move, and another line stated Laurus Labs’ current share price as ₹1,529.2. These values likely reflect different timestamps and data sources within the compiled text.

Board meeting and dividend consideration

The company has a board meeting scheduled for July 24, 2026, to consider the audited financial results and recommend a dividend for FY 2026-2027, as stated in the provided content. This date is also listed under “Quick Details” as the results date.

At the same time, a separate preview note included in the inputs mentioned that the Q1 results date is “not yet officially announced” and described the typical practice of disclosure through a board meeting notice. Readers should treat July 24, 2026 as the scheduled meeting date mentioned in the same dataset, while noting the presence of inconsistent statements across sources.

Earnings call schedule and dial-in details

Laurus Labs has also scheduled a conference call on July 24, 2026 at 5:00 PM IST to discuss Q1 FY27 financial results, hosted by DAM Capital Advisors. The session is described as including a performance presentation and a Q&A segment.

Dial-in details listed in the content include +91 22 6280 1384 (primary), +91 22 7115 8285 (secondary), and access numbers for Singapore (+8001012045), Hong Kong (+800964448), USA (+18667462133), and the UK (+08081011573).

Business profile and segment mix in focus

The text describes Laurus Labs as an Indian multinational pharmaceutical and biotechnology company with a research and development focus, and an integrated model across APIs, finished dosage forms, and contract services. The company’s segments were listed as Generics API, Generics FDF, CDMO-Synthesis, and biotechnology through its subsidiary Laurus Bio.

The company is also described as a global manufacturer of APIs for antiretroviral (ARV) drugs used in HIV treatment, alongside being a player in CDMO services for global pharmaceutical companies.

What investors are watching into Q1 FY27

The inputs highlight two near-term factors for the quarter: momentum in the CDMO segment and the currency backdrop. A year-on-year rupee depreciation of 12-14% was cited, with the rupee moving from a range of ₹83-84 in Q1 FY26 to ₹94.50-97.00 in Q1 FY27. The material frames this as supportive for export-led growth.

Margins are another key watch item. The text states that EBITDA margins may expand versus the Q1 FY26 base of 24.85% and could remain near the Q4 FY26 level of 28.27%, aided by operating leverage and a favourable CDMO product mix.

The ARV API segment is flagged as facing revenue erosion, but its “diluting share” in total revenue is expected to moderate the impact on overall growth, as per the preview commentary included in the dataset.

Working capital and inventory signals

Working capital is explicitly called out as a monitorable item. The inputs mention an inventory build of ₹141 crore in Q4 FY26, and note that total inventories reached “₹” but the figure is truncated in the provided text. Given the incomplete inventory total, only the stated build amount can be treated as confirmed.

FY26 performance points cited in the material

The dataset states Laurus Labs recorded ₹6,813 crore in annual revenue during FY2026, with a growth of 23% over the previous year. This growth is described as being driven by significant expansion in the CDMO business, supported by its Affordable Medicine portfolio, which the text links with generics.

Profitability metrics were also cited: gross margins were said to be maintained around the 60% range, while EBITDA margin expanded by 6.7 percentage points to 26.8% in FY26. Another line adds that Q4 EBITDA margin reached nearly 29%.

The CDMO business mix was described as increasing from 13% six years back to over 30% “right now”, and another expectation cited is CDMO revenues reaching 50% of overall sales by FY2030.

Quarterly financial snapshots provided

Two different quarterly result tables are included in the inputs, with figures that may reflect different scopes (for example, consolidated versus another basis). One table lists Mar 2026 net sales at ₹1,580.3 crore, while another consolidated sequence shows Mar 2026 revenue at ₹1,812 crore.

The “Quick Details” section in the content lists the previous quarter revenue at ₹1,812 crore, previous quarter PAT at ₹282 crore, and previous quarter EBITDA margin at 28.27%.

Cash flow datapoints from the provided table

A cash flow table (figures in ₹ crore) shows operating cash flow (OCF) of ₹1,384.95 crore for Mar 2026, versus ₹540.06 crore for Mar 2025. It also lists tax paid of -₹285.56 crore for Mar 2026.

These numbers provide context on cash generation trends across years, without requiring assumptions on quarter-specific movements.

Key numbers at a glance

Corporate update mentioned

The compiled inputs also state that Mrs. Aruna Bhinge’s tenure as Independent Director concluded on July 6, 2026, after completion of her second term.

What to track on July 24

With the board meeting and the scheduled call on July 24, investors are likely to focus on (1) the sustainability of CDMO-led growth, (2) margin trajectory relative to the stated 24.85% (Q1 FY26 base) and 28.27% (Q4 FY26) reference points, and (3) working-capital discipline following the cited ₹141 crore inventory build in Q4 FY26.

Any dividend recommendation for FY 2026-2027, as referenced in the board meeting agenda, will also be a key disclosure to track alongside the reported numbers and management commentary on pipeline and capacity investments cited in the material.